Tocilizumab for antibody-mediated rejection treatment in lung transplantation
Copyright © 2023 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved..
Tocilizumab (TCZ), an IL-6 inhibitor, has shown promise in the treatment of donor-specific antibodies (DSA) and chronic antibody-mediated rejection (AMR) in renal transplant recipients. However, its use in lung transplantation has not been described. This retrospective case-control study compared AMR treatments containing TCZ in 9 bilateral lung transplant recipients to 18 patients treated for AMR without TCZ. Treatment with TCZ resulted in more clearance of DSA, lower recurrence of DSA, lower incidence of new DSA, and lower rates of graft failure when compared to those treated for AMR without TCZ. The incidence of infusion reactions, elevation in transaminases, and infections were similar between the 2 groups. These data support a role for TCZ in pulmonary AMR and establish preliminary evidence to design a randomized controlled trial of IL-6 inhibition for the management of AMR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 42(2023), 10 vom: 19. Okt., Seite 1353-1357 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
January, Spenser E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.09.2023 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.healun.2023.05.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357700856 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357700856 | ||
| 003 | DE-627 | ||
| 005 | 20240210232533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2023.05.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM357700856 | ||
| 035 | |a (NLM)37268051 | ||
| 035 | |a (PII)S1053-2498(23)01866-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a January, Spenser E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab for antibody-mediated rejection treatment in lung transplantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Tocilizumab (TCZ), an IL-6 inhibitor, has shown promise in the treatment of donor-specific antibodies (DSA) and chronic antibody-mediated rejection (AMR) in renal transplant recipients. However, its use in lung transplantation has not been described. This retrospective case-control study compared AMR treatments containing TCZ in 9 bilateral lung transplant recipients to 18 patients treated for AMR without TCZ. Treatment with TCZ resulted in more clearance of DSA, lower recurrence of DSA, lower incidence of new DSA, and lower rates of graft failure when compared to those treated for AMR without TCZ. The incidence of infusion reactions, elevation in transaminases, and infections were similar between the 2 groups. These data support a role for TCZ in pulmonary AMR and establish preliminary evidence to design a randomized controlled trial of IL-6 inhibition for the management of AMR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a antibody-mediated rejection | |
| 650 | 4 | |a donor-specific antibodies | |
| 650 | 4 | |a interleukin-6 inhibition | |
| 650 | 4 | |a lung transplantation | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Isoantibodies |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a HLA Antigens |2 NLM | |
| 700 | 1 | |a Fester, Keith A |e verfasserin |4 aut | |
| 700 | 1 | |a Halverson, Laura P |e verfasserin |4 aut | |
| 700 | 1 | |a Witt, Chad A |e verfasserin |4 aut | |
| 700 | 1 | |a Byers, Derek E |e verfasserin |4 aut | |
| 700 | 1 | |a Vazquez-Guillamet, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander-Brett, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Tague, Laneshia K |e verfasserin |4 aut | |
| 700 | 1 | |a Kreisel, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Gelman, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Puri, Varun |e verfasserin |4 aut | |
| 700 | 1 | |a Bahena, Ruben Nava |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Tsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hachem, Ramsey R |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Hrishikesh S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation |d 1993 |g 42(2023), 10 vom: 19. Okt., Seite 1353-1357 |w (DE-627)NLM012612367 |x 1557-3117 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:10 |g day:19 |g month:10 |g pages:1353-1357 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healun.2023.05.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 10 |b 19 |c 10 |h 1353-1357 | ||